Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer and Metastasis Reviews
Published in: Cancer and Metastasis Reviews 3-4/2011

01-12-2011

Cyclooxygenases and lipoxygenases in cancer

Authors: Claus Schneider, Ambra Pozzi

Published in: Cancer and Metastasis Reviews | Issue 3-4/2011

Login to get access

Abstract

Cancer initiation and progression are multistep events that require cell proliferation, migration, extravasation to the blood or lymphatic vessels, arrest to the metastatic site, and ultimately secondary growth. Tumor cell functions at both primary or secondary sites are controlled by many different factors, including growth factors and their receptors, chemokines, nuclear receptors, cell–cell interactions, cell–matrix interactions, as well as oxygenated metabolites of arachidonic acid. The observation that cyclooxygenases and lipoxygenases and their arachidonic acid-derived eicosanoid products (prostanoids and HETEs) are expressed and produced by tumor cells, together with the finding that these enzymes can regulate cell growth, survival, migration, and invasion, has prompted investigators to analyze the roles of these enzymes in cancer progression. In this review, we focus on the contribution of cyclooxygenase- and lipoxygenase-derived eicosanoids to tumor cell function in vitro and in vivo and discuss hope and tribulations of targeting these enzymes for cancer prevention and treatment.
Literature
1.
Wang, D., & Dubois, R. N. (2010). Eicosanoids and cancer. Nature Reviews Cancer, 10, 181–193.PubMed
2.
Williams, C. S., Luongo, C., Radhika, A., Zhang, T., Lamps, L. W., Nanney, L. B., et al. (1996). Elevated cyclooxygenase-2 levels in Min mouse adenomas. Gastroenterology, 111, 1134–1140.PubMed
3.
Eberhart, C. E., Coffey, R. J., Radhika, A., Giardiello, F. M., Ferrenbach, S., & DuBois, R. N. (1994). Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology, 107, 1183–1188.PubMed
4.
Chen, W. S., Wei, S. J., Liu, J. M., Hsiao, M., Kou-Lin, J., & Yang, W. K. (2001). Tumor invasiveness and liver metastasis of colon cancer cells correlated with cyclooxygenase-2 (COX-2) expression and inhibited by a COX-2-selective inhibitor, etodolac. International Journal of Cancer, 91, 894–899.
5.
Gately, S. (2000). The contributions of cyclooxygenase-2 to tumor angiogenesis. Cancer Metastasis Reviews, 19, 19–27.PubMed
6.
Gately, S., & Li, W. W. (2004). Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy. Seminars in Oncology, 31, 2–11.PubMed
7.
Rizzo, M. T. (2011). Cyclooxygenase-2 in oncogenesis. Clinica Chimica Acta, 412, 671–687.
8.
Oshima, M., Dinchuk, J. E., Kargman, S. L., Oshima, H., Hancock, B., Kwong, E., et al. (1996). Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell, 87, 803–809.PubMed
9.
Oshima, M., Murai, N., Kargman, S., Arguello, M., Luk, P., Kwong, E., et al. (2001). Chemoprevention of intestinal polyposis in the Apcdelta716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor. Cancer Research, 61, 1733–1740.PubMed
10.
Rundhaug, J. E., & Fischer, S. M. (2008). Cyclo-oxygenase-2 plays a critical role in UV-induced skin carcinogenesis. Photochemistry and Photobiology, 84, 322–329.PubMed
11.
Stasinopoulos, I., O'Brien, D. R., Wildes, F., Glunde, K., & Bhujwalla, Z. M. (2007). Silencing of cyclooxygenase-2 inhibits metastasis and delays tumor onset of poorly differentiated metastatic breast cancer cells. Molecular Cancer Research, 5, 435–442.PubMed
12.
Ghosh, N., Chaki, R., Mandal, V., & Mandal, S. C. (2010). COX-2 as a target for cancer chemotherapy. Pharmacological Reports, 62, 233–244.PubMed
13.
Diczfalusy, U., Falardeau, P., & Hammarstrom, S. (1977). Conversion of prostaglandin endoperoxides to C17-hydroxy acids catalyzed by human platelet thromboxane synthase. FEBS Letters, 84, 271–274.PubMed
14.
Nakahata, N. (2008). Thromboxane A2: physiology/pathophysiology, cellular signal transduction and pharmacology. Pharmacology and Therapeutics, 118, 18–35.PubMed
15.
Cathcart, M. C., Gately, K., Cummins, R., Kay, E., O'Byrne, K. J., & Pidgeon, G. P. (2011). Examination of thromboxane synthase as a prognostic factor and therapeutic target in non-small cell lung cancer. Molecular Cancer, 10, 25.PubMed
16.
Huang, R. Y., & Chen, G. G. (2011). Cigarette smoking, cyclooxygenase-2 pathway and cancer. Biochimica et Biophysica Acta, 1815, 158–169.PubMed
17.
Huang, R. Y., Li, M. Y., Hsin, M. K., Underwood, M. J., Ma, L. T., Mok, T. S., et al. (2011). 4-Methylnitrosamino-1-3-pyridyl-1-butanone (NNK) promotes lung cancer cell survival by stimulating thromboxane A2 and its receptor. Oncogene, 30, 106–116.PubMed
18.
Leung, K. C., Li, M. Y., Leung, B. C., Hsin, M. K., Mok, T. S., Underwood, M. J., et al. (2010). Thromboxane synthase suppression induces lung cancer cell apoptosis via inhibiting NF-kappaB. Experimental Cell Research, 316, 3468–3477.PubMed
19.
Wei, J., Yan, W., Li, X., Ding, Y., & Tai, H. H. (2010). Thromboxane receptor alpha mediates tumor growth and angiogenesis via induction of vascular endothelial growth factor expression in human lung cancer cells. Lung Cancer, 69, 26–32.PubMed
20.
Wei, J., Yan, W., Li, X., Chang, W. C., & Tai, H. H. (2007). Activation of thromboxane receptor alpha induces expression of cyclooxygenase-2 through multiple signaling pathways in A549 human lung adenocarcinoma cells. Biochemical Pharmacology, 74, 787–800.PubMed
21.
Li, X., & Tai, H. H. (2009). Activation of thromboxane A(2) receptors induces orphan nuclear receptor Nurr1 expression and stimulates cell proliferation in human lung cancer cells. Carcinogenesis, 30, 1606–1613.PubMed
22.
Schmidt, N. O., Ziu, M., Cargioli, T., Westphal, M., Giese, A., Black, P. M., et al. (2010). Inhibition of thromboxane synthase activity improves glioblastoma response to alkylation chemotherapy. Transl Oncol, 3, 43–49.PubMed
23.
Schauff, A. K., Kim, E. L., Leppert, J., Nadrowitz, R., Wuestenberg, R., Brockmann, M. A., et al. (2009). Inhibition of invasion-associated thromboxane synthase sensitizes experimental gliomas to gamma-radiation. Journal of Neuro-Oncology, 91, 241–249.PubMed
24.
Cathcart, M. C., Reynolds, J. V., O'Byrne, K. J., & Pidgeon, G. P. (2010). The role of prostacyclin synthase and thromboxane synthase signaling in the development and progression of cancer. Biochimica et Biophysica Acta, 1805, 153–166.PubMed
25.
Tennis, M. A., Vanscoyk, M., Keith, R. L., & Winn, R. A. (2010). The role of prostacyclin in lung cancer. Translational Research, 155, 57–61.PubMed
26.
Keith, R. L., Miller, Y. E., Hudish, T. M., Girod, C. E., Sotto-Santiago, S., Franklin, W. A., et al. (2004). Pulmonary prostacyclin synthase overexpression chemoprevents tobacco smoke lung carcinogenesis in mice. Cancer Research, 64, 5897–5904.PubMed
27.
Keith, R. L., Karoor, V., Mozer, A. B., Hudish, T. M., Le, M., & Miller, Y. E. (2010). Chemoprevention of murine lung cancer by gefitinib in combination with prostacyclin synthase overexpression. Lung Cancer, 70, 37–42.PubMed
28.
Frigola, J., Munoz, M., Clark, S. J., Moreno, V., Capella, G., & Peinado, M. A. (2005). Hypermethylation of the prostacyclin synthase (PTGIS) promoter is a frequent event in colorectal cancer and associated with aneuploidy. Oncogene, 24, 7320–7326.PubMed
29.
Pehlivan, Y., Turkbeyler, I.H., Balakan, O., Sevinc, A., Yilmaz, M., Bakir, K., and Onat, A.M. (2011). Possible anti-metastatic effect of Iloprost in a patient with systemic sclerosis with lung cancer: a case study. Rheumatol Int (in press).
30.
Laubli, H., & Borsig, L. (2010). Selectins as mediators of lung metastasis. Cancer Microenvironment, 3, 97–105.PubMed
31.
Mohle, R., Green, D., Moore, M. A., Nachman, R. L., & Rafii, S. (1997). Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. Proceedings of the National Academy of Sciences of the United States of America, 94, 663–668.PubMed
32.
Tennis, M. A., Van Scoyk, M., Heasley, L. E., Vandervest, K., Weiser-Evans, M., Freeman, S., et al. (2010). Prostacyclin inhibits non-small cell lung cancer growth by a frizzled 9-dependent pathway that is blocked by secreted frizzled-related protein 1. Neoplasia, 12, 244–253.PubMed
33.
Nemenoff, R., Meyer, A. M., Hudish, T. M., Mozer, A. B., Snee, A., Narumiya, S., et al. (2008). Prostacyclin prevents murine lung cancer independent of the membrane receptor by activation of peroxisomal proliferator-activated receptor γ. Cancer Prevention Research (Philadelphia, Pa.), 1, 349–356.
34.
Hata, A. N., Lybrand, T. P., & Breyer, R. M. (2005). Identification of determinants of ligand binding affinity and selectivity in the prostaglandin D2 receptor CRTH2. Journal of Biological Chemistry, 280, 32442–32451.PubMed
35.
Hirai, H., Abe, H., Tanaka, K., Takatsu, K., Sugamura, K., Nakamura, M., et al. (2003). Gene structure and functional properties of mouse CRTH2, a prostaglandin D2 receptor. Biochemical and Biophysical Research Communications, 307, 797–802.PubMed
36.
Wright, D. H., Nantel, F., Metters, K. M., & Ford-Hutchinson, A. W. (1999). A novel biological role for prostaglandin D2 is suggested by distribution studies of the rat DP prostanoid receptor. European Journal of Pharmacology, 377, 101–115.PubMed
37.
Ragolia, L., Palaia, T., Hall, C. E., Klein, J., & Buyuk, A. (2010). Diminished lipocalin-type prostaglandin D(2) synthase expression in human lung tumors. Lung Cancer, 70, 103–109.PubMed
38.
Takeda, K., Takahashi, N. H., Yoshizawa, M., & Shibahara, S. (2010). Lipocalin-type prostaglandin D synthase as a regulator of the retinoic acid signalling in melanocytes. Journal of Biochemistry, 148, 139–148.PubMed
39.
Dionne, S., Levy, E., Levesque, D., & Seidman, E. G. (2010). PPARgamma ligand 15-deoxy-delta 12,14-prostaglandin J2 sensitizes human colon carcinoma cells to TWEAK-induced apoptosis. Anticancer Research, 30, 157–166.PubMed
40.
Wang, J. J., & Mak, O. T. (2011). Induction of apoptosis by 15d-PGJ2 via ROS formation: an alternative pathway without PPARgamma activation in non-small cell lung carcinoma A549 cells. Prostaglandins & Other Lipid Mediators, 94, 104–111.
41.
Passeron, T., Valencia, J. C., Namiki, T., Vieira, W. D., Passeron, H., Miyamura, Y., et al. (2009). Upregulation of SOX9 inhibits the growth of human and mouse melanomas and restores their sensitivity to retinoic acid. The Journal of Clinical Investigation, 119, 954–963.PubMed
42.
Murata, T., Lin, M. I., Aritake, K., Matsumoto, S., Narumiya, S., Ozaki, H., et al. (2008). Role of prostaglandin D2 receptor DP as a suppressor of tumor hyperpermeability and angiogenesis in vivo. Proceedings of the National Academy of Sciences of the United States of America, 105, 20009–20014.PubMed
43.
Kliewer, S. A., Lenhard, J. M., Willson, T. M., Patel, I., Morris, D. C., & Lehmann, J. M. (1995). A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation. Cell, 83, 813–819.PubMed
44.
Pozzi, A., and Capdevila, J.H. (2008). PPARα ligands as antitumorigenic and antiangiogenic agents. PPAR Res 2008, Article ID 906542.
45.
Diers, A. R., Dranka, B. P., Ricart, K. C., Oh, J. Y., Johnson, M. S., Zhou, F., et al. (2010). Modulation of mammary cancer cell migration by 15-deoxy-delta(12,14)-prostaglandin J(2): implications for anti-metastatic therapy. Biochemical Journal, 430, 69–78.PubMed
46.
Koyama, M., Izutani, Y., Goda, A. E., Matsui, T. A., Horinaka, M., Tomosugi, M., et al. (2010). Histone deacetylase inhibitors and 15-deoxy-Delta12,14-prostaglandin J2 synergistically induce apoptosis. Clinical Cancer Research, 16, 2320–2332.PubMed
47.
Shim, J., Kim, B. H., Kim, Y. I., Kim, K. Y., Hwangbo, Y., Jang, J. Y., et al. (2010). The peroxisome proliferator-activated receptor gamma ligands, pioglitazone and 15-deoxy-Delta(12,14)-prostaglandin J(2), have antineoplastic effects against hepatitis B virus-associated hepatocellular carcinoma cells. International Journal of Oncology, 36, 223–231.PubMed
48.
Cocca, C., Dorado, J., Calvo, E., Lopez, J. A., Santos, A., & Perez-Castillo, A. (2009). 15-Deoxi-Delta(12,14)-prostaglandin J2 is a tubulin-binding agent that destabilizes microtubules and induces mitotic arrest. Biochemical Pharmacology, 78, 1330–1339.PubMed
49.
Coyle, A. T., O'Keeffe, M. B., & Kinsella, B. T. (2005). 15-deoxy Delta12,14-prostaglandin J2 suppresses transcription by promoter 3 of the human thromboxane A2 receptor gene through peroxisome proliferator-activated receptor gamma in human erythroleukemia cells. FEBS Journal, 272, 4754–4773.PubMed
50.
Rossi, A., Kapahi, P., Natoli, G., Takahashi, T., Chen, Y., Karin, M., et al. (2000). Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IkappaB kinase. Nature, 403, 103–108.PubMed
51.
Dutta, J., Fan, Y., Gupta, N., Fan, G., & Gelinas, C. (2006). Current insights into the regulation of programmed cell death by NF-kappaB. Oncogene, 25, 6800–6816.PubMed
52.
Keightley, M. C., Sales, K. J., & Jabbour, H. N. (2010). PGF2alpha-F-prostanoid receptor signalling via ADAMTS1 modulates epithelial cell invasion and endothelial cell function in endometrial cancer. BMC Cancer, 10, 488.PubMed
53.
Sales, K. J., List, T., Boddy, S. C., Williams, A. R., Anderson, R. A., Naor, Z., et al. (2005). A novel angiogenic role for prostaglandin F2alpha-FP receptor interaction in human endometrial adenocarcinomas. Cancer Research, 65, 7707–7716.PubMed
54.
Sales, K. J., Boddy, S. C., Williams, A. R., Anderson, R. A., & Jabbour, H. N. (2007). F-prostanoid receptor regulation of fibroblast growth factor 2 signaling in endometrial adenocarcinoma cells. Endocrinology, 148, 3635–3644.PubMed
55.
Jabbour, H. N., Sales, K. J., Boddy, S. C., Anderson, R. A., & Williams, A. R. (2005). A positive feedback loop that regulates cyclooxygenase-2 expression and prostaglandin F2alpha synthesis via the F-series-prostanoid receptor and extracellular signal-regulated kinase 1/2 signaling pathway. Endocrinology, 146, 4657–4664.PubMed
56.
Sales, K. J., Boddy, S. C., & Jabbour, H. N. (2008). F-prostanoid receptor alters adhesion, morphology and migration of endometrial adenocarcinoma cells. Oncogene, 27, 2466–2477.PubMed
57.
Wallace, A. E., Catalano, R. D., Anderson, R. A., & Jabbour, H. N. (2011). Chemokine (C-C) motif ligand 20 is regulated by PGF(2alpha)-F-prostanoid receptor signalling in endometrial adenocarcinoma and promotes cell proliferation. Molecular and Cellular Endocrinology, 331, 129–135.PubMed
58.
Sales, K. J., Maldonado-Perez, D., Grant, V., Catalano, R. D., Wilson, M. R., Brown, P., et al. (2009). Prostaglandin F(2alpha)-F-prostanoid receptor regulates CXCL8 expression in endometrial adenocarcinoma cells via the calcium-calcineurin-NFAT pathway. Biochimica et Biophysica Acta, 1793, 1917–1928.PubMed
59.
Wallace, A. E., Sales, K. J., Catalano, R. D., Anderson, R. A., Williams, A. R., Wilson, M. R., et al. (2009). Prostaglandin F2alpha-F-prostanoid receptor signaling promotes neutrophil chemotaxis via chemokine (C-X-C motif) ligand 1 in endometrial adenocarcinoma. Cancer Research, 69, 5726–5733.PubMed
60.
Sugimoto, Y., & Narumiya, S. (2007). Prostaglandin E receptors. Journal of Biological Chemistry, 282, 11613–11617.PubMed
61.
Breyer, R. M., Bagdassarian, C. K., Myers, S. A., & Breyer, M. D. (2001). Prostanoid receptors: subtypes and signaling. Annual Review of Pharmacology and Toxicology, 41, 661–690.PubMed
62.
Nakanishi, M., Menoret, A., Tanaka, T., Miyamoto, S., Montrose, D.C., Vella, A., and Rosenberg, D.W. (2011). Selective PGE2 suppression impairs colon carcinogenesis and modifies local mucosal immunity. Cancer Prev Res (Phila), 4(8), 1198–1208.
63.
Hanaka, H., Pawelzik, S. C., Johnsen, J. I., Rakonjac, M., Terawaki, K., Rasmuson, A., et al. (2009). Microsomal prostaglandin E synthase 1 determines tumor growth in vivo of prostate and lung cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 106, 18757–18762.PubMed
64.
Regan, J. W. (2003). EP2 and EP4 prostanoid receptor signaling. Life Sciences, 74, 143–153.PubMed
65.
Fujino, H., Xu, W., & Regan, J. W. (2003). Prostaglandin E2 induced functional expression of early growth response factor-1 by EP4, but not EP2, prostanoid receptors via the phosphatidylinositol 3-kinase and extracellular signal-regulated kinases. Journal of Biological Chemistry, 278, 12151–12156.PubMed
66.
Pozzi, A., Yan, X., Macias-Perez, I., Wei, S., Hata, A. N., Breyer, R. M., et al. (2004). Colon carcinoma cell growth is associated with prostaglandin E2/EP4 receptor-evoked ERK activation. Journal of Biological Chemistry, 279, 29797–29804.PubMed
67.
Macias-Perez, I. M., Zent, R., Carmosino, M., Breyer, M. D., Breyer, R. M., & Pozzi, A. (2008). Mouse EP3 alpha, beta, and gamma receptor variants reduce tumor cell proliferation and tumorigenesis in vivo. Journal of Biological Chemistry, 283, 12538–12545.PubMed
68.
Surh, I., Rundhaug, J., Pavone, A., Mikulec, C., Abel, E., & Fischer, S. M. (2011). Upregulation of the EP1 receptor for prostaglandin E(2) promotes skin tumor progression. Molecular Carcinogenesis, 50, 458–468.PubMed
69.
Yang, S. F., Chen, M. K., Hsieh, Y. S., Chung, T. T., Hsieh, Y. H., Lin, C. W., et al. (2010). Prostaglandin E2/EP1 signaling pathway enhances intercellular adhesion molecule 1 (ICAM-1) expression and cell motility in oral cancer cells. Journal of Biological Chemistry, 285, 29808–29816.PubMed
70.
Liu, J. F., Fong, Y. C., Chang, C. S., Huang, C. Y., Chen, H. T., Yang, W. H., et al. (2010). Cyclooxygenase-2 enhances alpha2beta1 integrin expression and cell migration via EP1 dependent signaling pathway in human chondrosarcoma cells. Molecular Cancer, 9, 43.PubMed
71.
Ma, X., Kundu, N., Ioffe, O. B., Goloubeva, O., Konger, R., Baquet, C., et al. (2010). Prostaglandin E receptor EP1 suppresses breast cancer metastasis and is linked to survival differences and cancer disparities. Molecular Cancer Research, 8, 1310–1318.PubMed
72.
Axelsson, H., Lonnroth, C., Wang, W., Svanberg, E., & Lundholm, K. (2005). Cyclooxygenase inhibition in early onset of tumor growth and related angiogenesis evaluated in EP1 and EP3 knockout tumor-bearing mice. Angiogenesis, 8, 339–348.PubMed
73.
Sung, Y. M., He, G., & Fischer, S. M. (2005). Lack of expression of the EP2 but not EP3 receptor for prostaglandin E2 results in suppression of skin tumor development. Cancer Research, 65, 9304–9311.PubMed
74.
Tian, M., & Schiemann, W. P. (2010). PGE2 receptor EP2 mediates the antagonistic effect of COX-2 on TGF-beta signaling during mammary tumorigenesis. The FASEB Journal, 24, 1105–1116.PubMed
75.
Kuo, K. T., Wang, H. W., Chou, T. Y., Hsu, W. H., Hsu, H. S., Lin, C. H., et al. (2009). Prognostic role of PGE2 receptor EP2 in esophageal squamous cell carcinoma. Annals of Surgical Oncology, 16, 352–360.PubMed
76.
Takahashi, T., Ogawa, H., Izumi, K., & Uehara, H. (2011). The soluble EP2 receptor FuEP2/Ex2 suppresses endometrial cancer cell growth in an orthotopic xenograft model in nude mice. Cancer Letters, 306, 67–75.PubMed
77.
Kubo, H., Hosono, K., Suzuki, T., Ogawa, Y., Kato, H., Kamata, H., et al. (2010). Host prostaglandin EP3 receptor signaling relevant to tumor-associated lymphangiogenesis. Biomedicine and Pharmacotherapy, 64, 101–106.
78.
Amano, H., Ito, Y., Suzuki, T., Kato, S., Matsui, Y., Ogawa, F., et al. (2009). Roles of a prostaglandin E-type receptor, EP3, in upregulation of matrix metalloproteinase-9 and vascular endothelial growth factor during enhancement of tumor metastasis. Cancer Science, 100, 2318–2324.PubMed
79.
Amano, H., Hayashi, I., Endo, H., Kitasato, H., Yamashina, S., Maruyama, T., et al. (2003). Host prostaglandin E(2)-EP3 signaling regulates tumor-associated angiogenesis and tumor growth. The Journal of Experimental Medicine, 197, 221–232.PubMed
80.
Shoji, Y., Takahashi, M., Kitamura, T., Watanabe, K., Kawamori, T., Maruyama, T., et al. (2004). Downregulation of prostaglandin E receptor subtype EP3 during colon cancer development. Gut, 53, 1151–1158.PubMed
81.
Segi, E., Sugimoto, Y., Yamasaki, A., Aze, Y., Oida, H., Nishimura, T., et al. (1998). Patent ductus arteriosus and neonatal death in prostaglandin receptor EP4-deficient mice. Biochemical and Biophysical Research Communications, 246, 7–12.PubMed
82.
Cherukuri, D. P., Chen, X. B., Goulet, A. C., Young, R. N., Han, Y., Heimark, R. L., et al. (2007). The EP4 receptor antagonist, L-161,982, blocks prostaglandin E2-induced signal transduction and cell proliferation in HCA-7 colon cancer cells. Experimental Cell Research, 313, 2969–2979.PubMed
83.
Hawcroft, G., Ko, C. W., & Hull, M. A. (2007). Prostaglandin E2-EP4 receptor signalling promotes tumorigenic behaviour of HT-29 human colorectal cancer cells. Oncogene, 26, 3006–3019.PubMed
84.
Kim, J. I., Lakshmikanthan, V., Frilot, N., & Daaka, Y. (2010). Prostaglandin E2 promotes lung cancer cell migration via EP4-betaArrestin1-c-Src signalsome. Molecular Cancer Research, 8, 569–577.PubMed
85.
Yang, L., Huang, Y., Porta, R., Yanagisawa, K., Gonzalez, A., Segi, E., et al. (2006). Host and direct antitumor effects and profound reduction in tumor metastasis with selective EP4 receptor antagonism. Cancer Research, 66, 9665–9672.PubMed
86.
Terada, N., Shimizu, Y., Kamba, T., Inoue, T., Maeno, A., Kobayashi, T., et al. (2010). Identification of EP4 as a potential target for the treatment of castration-resistant prostate cancer using a novel xenograft model. Cancer Research, 70, 1606–1615.PubMed
87.
Schneider, A., Guan, Y., Zhang, Y., Magnuson, M. A., Pettepher, C., Loftin, C. D., et al. (2004). Generation of a conditional allele of the mouse prostaglandin EP4 receptor. Genesis, 40, 7–14.PubMed
88.
Rao, R., Redha, R., Macias-Perez, I., Su, Y., Hao, C., Zent, R., et al. (2007). Prostaglandin E2-EP4 receptor promotes endothelial cell migration via ERK activation and angiogenesis in vivo. Journal of Biological Chemistry, 282, 16959–16968.PubMed
89.
Pidgeon, G. P., Lysaght, J., Krishnamoorthy, S., Reynolds, J. V., O'Byrne, K., Nie, D., et al. (2007). Lipoxygenase metabolism: roles in tumor progression and survival. Cancer Metastasis Reviews, 26, 503–524.PubMed
90.
Soberman, R. J., Harper, T. W., Betteridge, D., Lewis, R. A., & Austen, K. F. (1985). Characterization and separation of the arachidonic acid 5-lipoxygenase and linoleic acid omega-6 lipoxygenase (arachidonic acid 15-lipoxygenase) of human polymorphonuclear leukocytes. Journal of Biological Chemistry, 260, 4508–4515.PubMed
91.
Bannenberg, G., & Serhan, C. N. (2010). Specialized pro-resolving lipid mediators in the inflammatory response: an update. Biochimica et Biophysica Acta, 1801, 1260–1273.PubMed
92.
Wasilewicz, M. P., Kolodziej, B., Bojulko, T., Kaczmarczyk, M., Sulzyc-Bielicka, V., Bielicki, D., et al. (2010). Overexpression of 5-lipoxygenase in sporadic colonic adenomas and a possible new aspect of colon carcinogenesis. International Journal of Colorectal Disease, 25, 1079–1085.PubMed
93.
Melstrom, L. G., Bentrem, D. J., Salabat, M. R., Kennedy, T. J., Ding, X. Z., Strouch, M., et al. (2008). Overexpression of 5-lipoxygenase in colon polyps and cancer and the effect of 5-LOX inhibitors in vitro and in a murine model. Clinical Cancer Research, 14, 6525–6530.PubMed
94.
Metzger, K., Angres, G., Maier, H., & Lehmann, W. D. (1995). Lipoxygenase products in human saliva: patients with oral cancer compared to controls. Free Radical Biology & Medicine, 18, 185–194.
95.
Yang, P., Sun, Z., Chan, D., Cartwright, C. A., Vijjeswarapu, M., Ding, J., et al. (2008). Zyflamend reduces LTB4 formation and prevents oral carcinogenesis in a 7,12-dimethylbenz[alpha]anthracene (DMBA)-induced hamster cheek pouch model. Carcinogenesis, 29, 2182–2189.PubMed
96.
Chen, Y., Hu, Y., Zhang, H., Peng, C., & Li, S. (2009). Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia. Nature Genetics, 41, 783–792.PubMed
97.
Shin, V. Y., Jin, H. C., Ng, E. K., Sung, J. J., Chu, K. M., & Cho, C. H. (2010). Activation of 5-lipoxygenase is required for nicotine mediated epithelial-mesenchymal transition and tumor cell growth. Cancer Letters, 292, 237–245.PubMed
98.
Schroeder, C. P., Yang, P., Newman, R. A., & Lotan, R. (2007). Simultaneous inhibition of COX-2 and 5-LOX activities augments growth arrest and death of premalignant and malignant human lung cell lines. Journal of Experimental Therapeutics and Oncology, 6, 183–192.PubMed
99.
Hayashi, T., Nishiyama, K., & Shirahama, T. (2006). Inhibition of 5-lipoxygenase pathway suppresses the growth of bladder cancer cells. International Journal of Urology, 13, 1086–1091.PubMed
100.
Chen, X., Wang, S., Wu, N., & Yang, C. S. (2004). Leukotriene A4 hydrolase as a target for cancer prevention and therapy. Current Cancer Drug Targets, 4, 267–283.PubMed
101.
Peters-Golden, M., & Brock, T. G. (2003). 5-Lipoxygenase and FLAP. Prostaglandins, Leukotrienes, and Essential Fatty Acids, 69, 99–109.PubMed
102.
Schweiger, D., Furstenberger, G., & Krieg, P. (2007). Inducible expression of 15-lipoxygenase-2 and 8-lipoxygenase inhibits cell growth via common signaling pathways. Journal of Lipid Research, 48, 553–564.PubMed
103.
Muga, S. J., Thuillier, P., Pavone, A., Rundhaug, J. E., Boeglin, W. E., Jisaka, M., et al. (2000). 8S-Lipoxygenase products activate peroxisome proliferator-activated receptor alpha and induce differentiation in murine keratinocytes. Cell Growth & Differentiation, 11, 447–454.
104.
Burger, F., Krieg, P., Kinzig, A., Schurich, B., Marks, F., & Furstenberger, G. (1999). Constitutive expression of 8-lipoxygenase in papillomas and clastogenic effects of lipoxygenase-derived arachidonic acid metabolites in keratinocytes. Molecular Carcinogenesis, 24, 108–117.PubMed
105.
Hagmann, W., Gao, X., Zacharek, A., Wojciechowski, L. A., & Honn, K. V. (1995). 12-Lipoxygenase in Lewis lung carcinoma cells: molecular identity, intracellular distribution of activity and protein, and Ca(2+)-dependent translocation from cytosol to membranes. Prostaglandins, 49, 49–62.PubMed
106.
Gao, X., Grignon, D. J., Chbihi, T., Zacharek, A., Chen, Y. Q., Sakr, W., et al. (1995). Elevated 12-lipoxygenase mRNA expression correlates with advanced stage and poor differentiation of human prostate cancer. Urology, 46, 227–237.PubMed
107.
Nithipatikom, K., Isbell, M. A., See, W. A., & Campbell, W. B. (2006). Elevated 12- and 20-hydroxyeicosatetraenoic acid in urine of patients with prostatic diseases. Cancer Letters, 233, 219–225.PubMed
108.
Tang, D. G., Chen, Y. Q., & Honn, K. V. (1996). Arachidonate lipoxygenases as essential regulators of cell survival and apoptosis. Proceedings of the National Academy of Sciences of the United States of America, 93, 5241–5246.PubMed
109.
Wong, B. C., Wang, W. P., Cho, C. H., Fan, X. M., Lin, M. C., Kung, H. F., et al. (2001). 12-Lipoxygenase inhibition induced apoptosis in human gastric cancer cells. Carcinogenesis, 22, 1349–1354.PubMed
110.
Pidgeon, G. P., Kandouz, M., Meram, A., & Honn, K. V. (2002). Mechanisms controlling cell cycle arrest and induction of apoptosis after 12-lipoxygenase inhibition in prostate cancer cells. Cancer Research, 62, 2721–2727.PubMed
111.
Nie, D., Hillman, G. G., Geddes, T., Tang, K., Pierson, C., Grignon, D. J., et al. (1998). Platelet-type 12-lipoxygenase in a human prostate carcinoma stimulates angiogenesis and tumor growth. Cancer Research, 58, 4047–4051.PubMed
112.
Tang, D. G., Renaud, C., Stojakovic, S., Diglio, C. A., Porter, A., & Honn, K. V. (1995). 12(S)-HETE is a mitogenic factor for microvascular endothelial cells: its potential role in angiogenesis. Biochemical and Biophysical Research Communications, 211, 462–468.PubMed
113.
Nie, D., Tang, K., Diglio, C., & Honn, K. V. (2000). Eicosanoid regulation of angiogenesis: role of endothelial arachidonate 12-lipoxygenase. Blood, 95, 2304–2311.PubMed
114.
Nie, D., Krishnamoorthy, S., Jin, R., Tang, K., Chen, Y., Qiao, Y., et al. (2006). Mechanisms regulating tumor angiogenesis by 12-lipoxygenase in prostate cancer cells. Journal of Biological Chemistry, 281, 18601–18609.PubMed
115.
Tang, D. G., Timar, J., Grossi, I. M., Renaud, C., Kimler, V. A., Diglio, C. A., et al. (1993). The lipoxygenase metabolite, 12(S)-HETE, induces a protein kinase C-dependent cytoskeletal rearrangement and retraction of microvascular endothelial cells. Experimental Cell Research, 207, 361–375.PubMed
116.
Tang, D. G., Chen, Y. Q., Diglio, C. A., & Honn, K. V. (1993). Protein kinase C-dependent effects of 12(S)-HETE on endothelial cell vitronectin receptor and fibronectin receptor. The Journal of Cell Biology, 121, 689–704.PubMed
117.
Brooks, P. C., Clark, R. A., & Cheresh, D. A. (1994). Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science, 264, 569–571.PubMed
118.
Kurahashi, Y., Herbertsson, H., Soderstrom, M., Rosenfeld, M. G., & Hammarstrom, S. (2000). A 12(S)-hydroxyeicosatetraenoic acid receptor interacts with steroid receptor coactivator-1. Proceedings of the National Academy of Sciences of the United States of America, 97, 5779–5783.PubMed
119.
Herbertsson, H., & Hammarstrom, S. (1997). Cytosolic 12(S)-hydroxy-5,8,10,14-eicosatetraenoic acid binding sites in carcinoma cells. Advances in Experimental Medicine and Biology, 400A, 287–293.PubMed
120.
Herbertsson, H., Kuhme, T., Evertsson, U., Wigren, J., & Hammarstrom, S. (1998). Identification of subunits of the 650 kDa 12(S)-HETE binding complex in carcinoma cells. Journal of Lipid Research, 39, 237–244.PubMed
121.
Herbertsson, H., Kuhme, T., & Hammarstrom, S. (1999). Subunits and cellular occurrence of the 12(S)-HETE binding complex. Advances in Experimental Medicine and Biology, 469, 253–258.PubMed
122.
Herbertsson, H., Kuhme, T., & Hammarstrom, S. (1999). The 650-kDa 12(S)-hydroxyeicosatetraenoic acid binding complex: occurrence in human platelets, identification of hsp90 as a constituent, and binding properties of its 50-kDa subunit. Archives of Biochemistry and Biophysics, 367, 33–38.PubMed
123.
Moreno, J. J. (2009). New aspects of the role of hydroxyeicosatetraenoic acids in cell growth and cancer development. Biochemical Pharmacology, 77, 1–10.PubMed
124.
Jiang, W. G., Watkins, G., Douglas-Jones, A., & Mansel, R. E. (2006). Reduction of isoforms of 15-lipoxygenase (15-LOX)-1 and 15-LOX-2 in human breast cancer. Prostaglandins, Leukotrienes, and Essential Fatty Acids, 74, 235–245.PubMed
125.
Shureiqi, I., Wu, Y., Chen, D., Yang, X. L., Guan, B., Morris, J. S., et al. (2005). The critical role of 15-lipoxygenase-1 in colorectal epithelial cell terminal differentiation and tumorigenesis. Cancer Research, 65, 11486–11492.PubMed
126.
Freedman, R. S., Wang, E., Voiculescu, S., Patenia, R., Bassett, R. L., Jr., Deavers, M., et al. (2007). Comparative analysis of peritoneum and tumor eicosanoids and pathways in advanced ovarian cancer. Clinical Cancer Research, 13, 5736–5744.PubMed
127.
Tang, D. G., Bhatia, B., Tang, S., & Schneider-Broussard, R. (2007). 15-Lipoxygenase 2 (15-LOX2) is a functional tumor suppressor that regulates human prostate epithelial cell differentiation, senescence, and growth (size). Prostaglandins & Other Lipid Mediators, 82, 135–146.
128.
Tang, S., Bhatia, B., Maldonado, C. J., Yang, P., Newman, R. A., Liu, J., et al. (2002). Evidence that arachidonate 15-lipoxygenase 2 is a negative cell cycle regulator in normal prostate epithelial cells. Journal of Biological Chemistry, 277, 16189–16201.PubMed
129.
Bhatia, B., Tang, S., Yang, P., Doll, A., Aumueller, G., Newman, R. A., et al. (2005). Cell-autonomous induction of functional tumor suppressor 15-lipoxygenase 2 (15-LOX2) contributes to replicative senescence of human prostate progenitor cells. Oncogene, 24, 3583–3595.PubMed
130.
Shappell, S. B., Boeglin, W. E., Olson, S. J., Kasper, S., & Brash, A. R. (1999). 15-Lipoxygenase-2 (15-LOX-2) is expressed in benign prostatic epithelium and reduced in prostate adenocarcinoma. American Journal of Pathology, 155, 235–245.PubMed
131.
Suraneni, M. V., Schneider-Broussard, R., Moore, J. R., Davis, T. C., Maldonado, C. J., Li, H., et al. (2010). Transgenic expression of 15-lipoxygenase 2 (15-LOX2) in mouse prostate leads to hyperplasia and cell senescence. Oncogene, 29, 4261–4275.PubMed
132.
Zuo, X., Wu, Y., Morris, J. S., Stimmel, J. B., Leesnitzer, L. M., Fischer, S. M., et al. (2006). Oxidative metabolism of linoleic acid modulates PPAR-beta/delta suppression of PPAR-gamma activity. Oncogene, 25, 1225–1241.PubMed
133.
Shureiqi, I., Jiang, W., Zuo, X., Wu, Y., Stimmel, J. B., Leesnitzer, L. M., et al. (2003). The 15-lipoxygenase-1 product 13-S-hydroxyoctadecadienoic acid down-regulates PPAR-delta to induce apoptosis in colorectal cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 100, 9968–9973.PubMed
134.
Keshamouni, V. G., Reddy, R. C., Arenberg, D. A., Joel, B., Thannickal, V. J., Kalemkerian, G. P., et al. (2004). Peroxisome proliferator-activated receptor-gamma activation inhibits tumor progression in non-small-cell lung cancer. Oncogene, 23, 100–108.PubMed
135.
Yuan, H., Li, M. Y., Ma, L. T., Hsin, M. K., Mok, T. S., Underwood, M. J., et al. (2010). 15-Lipoxygenases and its metabolites 15(S)-HETE and 13(S)-HODE in the development of non-small cell lung cancer. Thorax, 65, 321–326.PubMed
136.
Nixon, J. B., Kim, K. S., Lamb, P. W., Bottone, F. G., & Eling, T. E. (2004). 15-Lipoxygenase-1 has anti-tumorigenic effects in colorectal cancer. Prostaglandins, Leukotrienes, and Essential Fatty Acids, 70, 7–15.PubMed
137.
Mao, J. T., Nie, W. X., Tsu, I. H., Jin, Y. S., Rao, J. Y., Lu, Q. Y., et al. (2010). White tea extract induces apoptosis in non-small cell lung cancer cells: the role of peroxisome proliferator-activated receptor-γ and 15-lipoxygenases. Cancer Prevention Research (Philadelphia, Pa.), 3, 1132–1140.
138.
Harats, D., Ben-Shushan, D., Cohen, H., Gonen, A., Barshack, I., Goldberg, I., et al. (2005). Inhibition of carcinogenesis in transgenic mouse models over-expressing 15-lipoxygenase in the vascular wall under the control of murine preproendothelin-1 promoter. Cancer Letters, 229, 127–134.PubMed
139.
Viita, H., Markkanen, J., Eriksson, E., Nurminen, M., Kinnunen, K., Babu, M., et al. (2008). 15-Lipoxygenase-1 prevents vascular endothelial growth factor A- and placental growth factor-induced angiogenic effects in rabbit skeletal muscles via reduction in growth factor mRNA levels, NO bioactivity, and downregulation of VEGF receptor 2 expression. Circulation Research, 102, 177–184.PubMed
140.
Sauer, L. A., Dauchy, R. T., Blask, D. E., Armstrong, B. J., & Scalici, S. (1999). 13-Hydroxyoctadecadienoic acid is the mitogenic signal for linoleic acid-dependent growth in rat hepatoma 7288CTC in vivo. Cancer Research, 59, 4688–4692.PubMed
141.
Kelavkar, U. P., Cohen, C., Kamitani, H., Eling, T. E., & Badr, K. F. (2000). Concordant induction of 15-lipoxygenase-1 and mutant p53 expression in human prostate adenocarcinoma: correlation with Gleason staging. Carcinogenesis, 21, 1777–1787.PubMed
142.
Kelavkar, U. P., Glasgow, W., Olson, S. J., Foster, B. A., & Shappell, S. B. (2004). Overexpression of 12/15-lipoxygenase, an ortholog of human 15-lipoxygenase-1, in the prostate tumors of TRAMP mice. Neoplasia, 6, 821–830.PubMed
143.
Planaguma, A., Kazani, S., Marigowda, G., Haworth, O., Mariani, T. J., Israel, E., et al. (2008). Airway lipoxin A4 generation and lipoxin A4 receptor expression are decreased in severe asthma. American Journal of Respiratory and Critical Care Medicine, 178, 574–582.PubMed
144.
Kieran, N. E., Maderna, P., & Godson, C. (2004). Lipoxins: potential anti-inflammatory, proresolution, and antifibrotic mediators in renal disease. Kidney International, 65, 1145–1154.PubMed
145.
Chen, Y., Hao, H., He, S., Cai, L., Li, Y., Hu, S., et al. (2010). Lipoxin A4 and its analogue suppress the tumor growth of transplanted H22 in mice: the role of antiangiogenesis. Molecular Cancer Therapeutics, 9, 2164–2174.PubMed
146.
Liu, S., Wu, P., Ye, D., Huang, Y., Zhou, X., Li, Y., et al. (2009). Effects of lipoxin A(4) on CoCl(2)-induced angiogenesis and its possible mechanisms in human umbilical vein endothelial cells. Pharmacology, 84, 17–23.PubMed
147.
Cezar-de-Mello, P. F., Nascimento-Silva, V., Villela, C. G., & Fierro, I. M. (2006). Aspirin-triggered Lipoxin A4 inhibition of VEGF-induced endothelial cell migration involves actin polymerization and focal adhesion assembly. Oncogene, 25, 122–129.PubMed
148.
Cezar-de-Mello, P. F., Vieira, A. M., Nascimento-Silva, V., Villela, C. G., Barja-Fidalgo, C., & Fierro, I. M. (2008). ATL-1, an analogue of aspirin-triggered lipoxin A4, is a potent inhibitor of several steps in angiogenesis induced by vascular endothelial growth factor. British Journal of Pharmacology, 153, 956–965.PubMed
149.
Schneider, C., Boeglin, W. E., Yin, H., Stec, D. F., & Voehler, M. (2006). Convergent oxygenation of arachidonic acid by 5-lipoxygenase and cyclooxygenase-2. Journal of the American Chemical Society, 128, 720–721.PubMed
150.
Griesser, M., Suzuki, T., Tejera, N., Mont, S., Boeglin, W. E., Pozzi, A., et al. (2011). Biosynthesis of hemiketal eicosanoids by cross-over of the 5-lipoxygenase and cyclooxygenase-2 pathways. Proceedings of the National Academy of Sciences of the United States of America, 108, 6945–6950.PubMed
151.
Nie, D., & Honn, K. V. (2002). Cyclooxygenase, lipoxygenase and tumor angiogenesis. Cellular and Molecular Life Sciences, 59, 799–807.PubMed
152.
Tong, W. G., Ding, X. Z., Witt, R. C., & Adrian, T. E. (2002). Lipoxygenase inhibitors attenuate growth of human pancreatic cancer xenografts and induce apoptosis through the mitochondrial pathway. Molecular Cancer Therapeutics, 1, 929–935.PubMed
153.
Agarwal, S., Achari, C., Praveen, D., Roy, K. R., Reddy, G. V., & Reddanna, P. (2009). Inhibition of 12-LOX and COX-2 reduces the proliferation of human epidermoid carcinoma cells (A431) by modulating the ERK and PI3K-Akt signalling pathways. Experimental Dermatology, 18, 939–946.PubMed
154.
Pergola, C., & Werz, O. (2010). 5-Lipoxygenase inhibitors: a review of recent developments and patents. Expert Opinion on Therapeutic Patents, 20, 355–375.PubMed
155.
Bolger, J. K., Tian, W., Wolter, W. R., Cho, W., Suckow, M. A., & Miller, M. J. (2011). Synthesis and evaluation of 5-lipoxygenase translocation inhibitors from acylnitroso hetero-Diels-Alder cycloadducts. Organic and Biomolecular Chemistry, 9, 2999–3010.PubMed
156.
Reddy, N. P., Aparoy, P., Reddy, T. C., Achari, C., Sridhar, P. R., & Reddanna, P. (2010). Design, synthesis, and biological evaluation of prenylated chalcones as 5-LOX inhibitors. Bioorganic & Medicinal Chemistry, 18, 5807–5815.
157.
Sarveswaran, S., Myers, C. E., & Ghosh, J. (2010). MK591, a leukotriene biosynthesis inhibitor, induces apoptosis in prostate cancer cells: synergistic action with LY294002, an inhibitor of phosphatidylinositol 3'-kinase. Cancer Letters, 291, 167–176.PubMed
158.
Fischer, A. S., Metzner, J., Steinbrink, S. D., Ulrich, S., Angioni, C., Geisslinger, G., et al. (2010). 5-Lipoxygenase inhibitors induce potent anti-proliferative and cytotoxic effects in human tumour cells independently of suppression of 5-lipoxygenase activity. British Journal of Pharmacology, 161, 936–949.PubMed
159.
Thun, M. J., Namboodiri, M. M., & Heath, C. W., Jr. (1991). Aspirin use and reduced risk of fatal colon cancer. The New England Journal of Medicine, 325, 1593–1596.PubMed
160.
Gupta, R. A., & Dubois, R. N. (2001). Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nature Reviews. Cancer, 1, 11–21.PubMed
161.
Cha, Y. I., & DuBois, R. N. (2007). NSAIDs and cancer prevention: targets downstream of COX-2. Annual Review of Medicine, 58, 239–252.PubMed
162.
Witton, C. J., Hawe, S. J., Cooke, T. G., & Bartlett, J. M. (2004). Cyclooxygenase 2 (COX2) expression is associated with poor outcome in ER-negative, but not ER-positive, breast cancer. Histopathology, 45, 47–54.PubMed
163.
(2005). FDA warning on NSAID use. FDA Consum 39:5.
164.
Mukherjee, D. (2008). Nonsteroidal anti-inflammatory drugs and the heart: what is the danger? Congestive Heart Failure, 14, 75–82.PubMed
165.
Grosser, T., Fries, S., & FitzGerald, G. A. (2006). Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. The Journal of Clinical Investigation, 116, 4–15.PubMed
166.
Zhang, M. Z., Xu, J., Yao, B., Yin, H., Cai, Q., Shrubsole, M. J., et al. (2009). Inhibition of 11beta-hydroxysteroid dehydrogenase type II selectively blocks the tumor COX-2 pathway and suppresses colon carcinogenesis in mice and humans. The Journal of Clinical Investigation, 119, 876–885.PubMed
167.
Cerella, C., Sobolewski, C., Dicato, M., & Diederich, M. (2010). Targeting COX-2 expression by natural compounds: a promising alternative strategy to synthetic COX-2 inhibitors for cancer chemoprevention and therapy. Biochemical Pharmacology, 80, 1801–1815.PubMed
168.
Jang, M., & Pezzuto, J. M. (1999). Cancer chemopreventive activity of resveratrol. Drugs Under Experimental and Clinical Research, 25, 65–77.PubMed
169.
Subbaramaiah, K., Chung, W. J., Michaluart, P., Telang, N., Tanabe, T., Inoue, H., et al. (1998). Resveratrol inhibits cyclooxygenase-2 transcription and activity in phorbol ester-treated human mammary epithelial cells. Journal of Biological Chemistry, 273, 21875–21882.PubMed
170.
Kundu, J. K., Na, H. K., Chun, K. S., Kim, Y. K., Lee, S. J., Lee, S. S., et al. (2003). Inhibition of phorbol ester-induced COX-2 expression by epigallocatechin gallate in mouse skin and cultured human mammary epithelial cells. Journal of Nutrition, 133, 3805S–3810S.PubMed
171.
Woo, E. R., Pokharel, Y. R., Yang, J. W., Lee, S. Y., & Kang, K. W. (2006). Inhibition of nuclear factor-kappaB activation by 2',8''-biapigenin. Biological and Pharmaceutical Bulletin, 29, 976–980.PubMed
172.
Corona, G., Deiana, M., Incani, A., Vauzour, D., Dessi, M. A., & Spencer, J. P. (2007). Inhibition of p38/CREB phosphorylation and COX-2 expression by olive oil polyphenols underlies their anti-proliferative effects. Biochemical and Biophysical Research Communications, 362, 606–611.PubMed
173.
Barry, M., Cahill, R. A., Roche-Nagle, G., Neilan, T. G., Treumann, A., Harmey, J. H., et al. (2009). Neoplasms escape selective COX-2 inhibition in an animal model of breast cancer. Irish Journal of Medical Science, 178, 201–208.PubMed
174.
Ye, Y. N., Wu, W. K., Shin, V. Y., Bruce, I. C., Wong, B. C., & Cho, C. H. (2005). Dual inhibition of 5-LOX and COX-2 suppresses colon cancer formation promoted by cigarette smoke. Carcinogenesis, 26, 827–834.PubMed
175.
Laufer, S. A., Augustin, J., Dannhardt, G., & Kiefer, W. (1994). (6,7-Diaryldihydropyrrolizin-5-yl)acetic acids, a novel class of potent dual inhibitors of both cyclooxygenase and 5-lipoxygenase. Journal of Medicinal Chemistry, 37, 1894–1897.PubMed
176.
Fiorucci, S., Meli, R., Bucci, M., & Cirino, G. (2001). Dual inhibitors of cyclooxygenase and 5-lipoxygenase. A new avenue in anti-inflammatory therapy? Biochemical Pharmacology, 62, 1433–1438.PubMed
177.
Rao, P. N., Chen, Q. H., & Knaus, E. E. (2006). Synthesis and structure-activity relationship studies of 1,3-diarylprop-2-yn-1-ones: dual inhibitors of cyclooxygenases and lipoxygenases. Journal of Medicinal Chemistry, 49, 1668–1683.PubMed
178.
Rao, P., & Knaus, E. E. (2008). Evolution of nonsteroidal anti-inflammatory drugs (NSAIDs): cyclooxygenase (COX) inhibition and beyond. Journal of Pharmacy and Pharmaceutical Sciences, 11, 81s–110s.PubMed
179.
Rao, C. V. (2007). Regulation of COX and LOX by curcumin. Advances in Experimental Medicine and Biology, 595, 213–226.PubMed
180.
Zhang, F., Altorki, N. K., Mestre, J. R., Subbaramaiah, K., & Dannenberg, A. J. (1999). Curcumin inhibits cyclooxygenase-2 transcription in bile acid- and phorbol ester-treated human gastrointestinal epithelial cells. Carcinogenesis, 20, 445–451.PubMed
181.
Huang, M. T., Lysz, T., Ferraro, T., Abidi, T. F., Laskin, J. D., & Conney, A. H. (1991). Inhibitory effects of curcumin on in vitro lipoxygenase and cyclooxygenase activities in mouse epidermis. Cancer Research, 51, 813–819.PubMed
182.
Griesser, M., Pistis, V., Suzuki, T., Tejera, N., Pratt, D. A., & Schneider, C. (2011). Autoxidative and cyclooxygenase-2 catalyzed transformation of the dietary chemopreventive agent curcumin. Journal of Biological Chemistry, 286, 1114–1124.PubMed
183.
Ohashi, Y., Tsuchiya, Y., Koizumi, K., Sakurai, H., & Saiki, I. (2003). Prevention of intrahepatic metastasis by curcumin in an orthotopic implantation model. Oncology, 65, 250–258.PubMed
184.
Bengmark, S., Mesa, M. D., & Gil, A. (2009). Plant-derived health: the effects of turmeric and curcuminoids. Nutrición Hospitalaria, 24, 273–281.PubMed
185.
Zhang, B., Wang, C. L., Zhao, W. H., Lv, M., Wang, C. Y., Zhong, W. X., et al. (2008). Effect of 5-LOX/COX-2 common inhibitor DHDMBF30 on pancreatic cancer cell Capan2. World Journal of Gastroenterology, 14, 2494–2500.PubMed
186.
Bridoux, A., Millet, R., Pommery, J., Pommery, N., & Henichart, J. P. (2010). Synthesis and biological activity of N-aroyl-tetrahydro-gamma-carbolines. Bioorganic & Medicinal Chemistry, 18, 3910–3924.
187.
Pontiki, E., Hadjipavlou-Litina, D., Litinas, K., Nicolotti, O., & Carotti, A. (2011). Design, synthesis and pharmacobiological evaluation of novel acrylic acid derivatives acting as lipoxygenase and cyclooxygenase-1 inhibitors with antioxidant and anti-inflammatory activities. European Journal of Medicinal Chemistry, 46, 191–200.PubMed
188.
Tauler, J., & Mulshine, J. L. (2008). Combination therapy of PPARgamma ligands and inhibitors of arachidonic acid in lung cancer. PPAR Research, 2008, 750238.PubMed
189.
Hanif, R., Pittas, A., Feng, Y., Koutsos, M. I., Qiao, L., Staiano-Coico, L., et al. (1996). Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway. Biochemical Pharmacology, 52, 237–245.PubMed
190.
Piazza, G. A., Alberts, D. S., Hixson, L. J., Paranka, N. S., Li, H., Finn, T., et al. (1997). Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. Cancer Research, 57, 2909–2915.PubMed
Metadata
Title
Cyclooxygenases and lipoxygenases in cancer
Authors
Claus Schneider
Ambra Pozzi
Publication date
01-12-2011
Publisher
Springer US
Published in
Cancer and Metastasis Reviews / Issue 3-4/2011
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-011-9310-3

Other articles of this Issue 3-4/2011

Cancer and Metastasis Reviews 3-4/2011 Go to the issue

OriginalPaper

15-Lipoxygenase-1 as a tumor suppressor gene in colon cancer: is the verdict in?

OriginalPaper

Prostaglandin catabolic enzymes as tumor suppressors

OriginalPaper

The thromboxane synthase and receptor signaling pathway in cancer: an emerging paradigm in cancer progression and metastasis

OriginalPaper

Hepoxilins in cancer and inflammation—use of hepoxilin antagonists

OriginalPaper

Cyclooxygenase-2 and Gastric Cancer

OriginalPaper

Eicosanoids and other lipid mediators and the tumor hypoxic microenvironment
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits